CG Oncology, Inc.'s promising bladder cancer therapy has strong clinical results, competitive CR rates, and a $69 target ...

The worse part is the timeliness issues with the earnings reports for these developing companies. Red Cat didn't report Q4 ...

Discover why DNP's reliable distributions attract income investors and explore why DPG might be a smarter buy right now.

Advanced Micro Devices, Inc. faces challenges in the slowing AI market, with Nvidia's dominance and custom chips reshaping ...

TG Therapeutics (TGTX) stock spikes as Roche (RHHBY) fails in a Phase 3 trial for a high dose version of its multiple ...

CoreWeave’s 2022 to 2024 financial path is one of hypergrowth, efficiency improvement, and early-stage profitability. In 2022 ...

Will tariffs cause inflation and higher interest rates? Jitania Kandhari discusses how subsidies, sanctions & security ...

Nebius's diversified revenue streams, lack of debt, and positioning in Europe make it a clear buy over CoreWeave. Learn more about NBIS stock here.

BB Seguridade Participações S.A. offers a 9% dividend yield but is overvalued. Click for my look at BBSEY stock and its big ...

Exxon Mobil's stock remains steady year-over-year. Learn why the recent price rise may not last and explore its long-term growth potential in the energy sector. Read why XOM stock is a hold.

Delcath's Q4 sales exceeded expectations due to HEPZATO KIT adoption. Discover insights into its profitability, CHOPIN trial ...

Overall, the fourth quarter of 2024 was characterized by resilient labor market dynamics, strong economic growth and sticky ...